Dextera Biosciences
Sarah Chapman is currently the Director of Corporate Strategy at Dextera Biosciences. Previously, Sarah worked as a Biopharmaceutical Strategy Consultant at Chapman Biomedical Consulting Ltd. and as a Consultant at ClearView Healthcare Partners, focusing on strategy consulting for life sciences companies. Sarah also has experience in academic research at Harvard University and the Karolinska Institutet Department of Cell and Molecular Biology. Sarah holds a Bachelor's Degree in Human Developmental and Regenerative Biology from Harvard University, graduating Summa Cum Laude.
This person is not in any teams
This person is not in any offices
Dextera Biosciences
Dextera Biosciences is developing a new category of drugs, Synthetic D-Proteins, to overcome the limitations of current drug modalities. Synthetic D-Proteins exhibit antibody-like specificity to a single therapeutic target but with the broad distribution of small molecules, all while being otherwise “invisible” to the rest of the body. The consequences are that we can deliver sustained antibody-like activity specifically to interstitial targets, enable oral delivery with complete metabolic stability, and extend therapeutic durability with no immunogenicity. We are focusing on debilitating diseases where significant unmet need remains due to the limitations of current drugs.